Navigation Links
Tengion Scientists Publish Positive Preclinical Findings With Neo-Organ Demonstrating Long-term Durability and Growth With Skeletal Maturation
Date:9/18/2008

Study Showing Results of Tengion Neo-Bladder Augment(TM) Featured in

September Issue of Regenerative Medicine

EAST NORRITON, Pa., Sept. 18 /PRNewswire/ -- Tengion Inc., a clinical stage regenerative medicine company focused on the development of neo-organs and neo-tissues, today announced that the results of a preclinical research study conducted with its Tengion Neo-Bladder Augment(TM) were published in the September issue of the Regenerative Medicine, Vol. 3, Issue 5. The paper, "Long-term durability, tissue regeneration and neo-organ growth during skeletal maturation with a Neo-Bladder Augmentation Construct" was co-authored by Tengion scientists Manuel J. Jayo, D.V.M., Ph.D., Deepak Jain, Ph.D., John W. Ludlow, Ph.D., Richard Payne, Ph.D., Belinda J. Wagner, Ph.D., and Timothy A. Bertram, D.V.M., Ph.D. along with Gordon McLorie, MD from Wake Forest University Baptist Medical Center. The article can be accessed via the website http://www.futuremedicine.com/doi/abs/10.2217/17460751.3.5.671

The preclinical study, in which either a Neo-Bladder Augment or the subject's own native urinary bladder was surgically implanted following an 80% cystectomy and evaluated clinically at one, three, six, nine, 12, 18 and 24 months - showed that the Tengion Neo-Bladder Augment regained and maintained native bladder histology by three months. The study also demonstrated that the Neo-Bladder Augment regained baseline capacity at three to six months and baseline compliance by 12-24 months. Importantly, the Neo-Bladder Augment continued to adapt in size and function with overall animal growth, or skeletal maturation.

"The results of this study are very encouraging for our overall Neo-Bladder Augment program and, specifically, for our ongoing Neo-Bladder Augment pediatric clinical trial. The children with spina bifida in that trial are continuing to grow and mature and our goal is for the Neo-Bladder Augment to demonstrate durability and the ability to adapt to growth-related changes - as it has done in this pre-clinical model," said Dr. Bertram, Senior Vice President, Science and Technology of Tengion, "Tengion is truly excited to continue to share positive research results that help to further advance our neo-organ pipeline, and continue to validate our Autologous Organ Regeneration Platform(TM)."

About Tengion

Tengion, a clinical stage biotechnology company, focuses on developing, manufacturing and commercializing human neo-organs and neo-tissues using our Autologous Organ Regeneration Platform(TM). Tengion uses biocompatible materials and a patient's own (autologous) cells to create a functional neo-organ or neo-tissue that is designed to catalyze the body's innate ability to regenerate. Tengion's product candidates may ultimately address the most critical problems facing organ and tissue failure patients, enabling people to lead healthier lives without donor transplants or the side effects of related therapies.


'/>"/>
SOURCE Tengion Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Preclinical Efficacy Data Demonstrate Ability of Tengions Neo-Bladder Augment to Restore Bladder Function
2. Tengion to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
3. Tengion Appoints Jeff Randall to Board of Directors
4. Tengion Announces European Orphan Drug Designation for Neo-Bladder Augment
5. Tengion Appoints Mark Stejbach Vice President of Marketing & Commercial Planning
6. Gladstone scientists uncover potential mechanism of memory loss in Alzheimers disease
7. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
8. Social Network for Scientists Marks Ten Years Online
9. Scientists synthesize memory in yeast cells
10. Scientists synthesize memory in yeast cells
11. University of Leicester scientists discover technique to help friendly bacteria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... (PRWEB) , ... February 09, 2016 , ... ... its latest innovations on its free and validated Electronic Data Capture (EDC) system ... the Outsourcing in Clinical Trials West Coast 2016 Conference in San Mateo, California ...
(Date:2/9/2016)... 9, 2016  DNAtrix, a clinical stage, ... announced that its lead product, DNX-2401, has ... an orphan medicinal product for the treatment ... glioma, strikes approximately 25,000 people a year ... http://photos.prnewswire.com/prnh/20160208/330986LOGO --> http://photos.prnewswire.com/prnh/20160208/330986LOGO ...
(Date:2/9/2016)... Feb. 9, 2016 ... 2016", report provides in depth insights on ... around the Protein-Tyrosine Phosphatase 1B (PTP1B) Inhibitors. ... in various stages of development including Discovery, ... III and Preregistration. Report covers the product ...
(Date:2/8/2016)... 8, 2016 Novan, Inc. today announced that Director ... of Directors of Novan. In addition, Robert Keegan has ... North Carolina . --> North Carolina ... it received a total of $32.8 million of net proceeds in ... investor network originating throughout the Research Triangle area of ...
Breaking Biology Technology:
(Date:2/2/2016)... , Feb. 2, 2016 This BCC ... bioinformatic market by reviewing the recent advances in ... that drive the field forward. Includes forecast through ... Identify the challenges and opportunities that exist in ... software solution developers, as well as IT and ...
(Date:2/2/2016)... 2016 Technology Enhancements Accelerate Growth of X-ray Imaging ... digital and computed radiography markets in Thailand ... Indonesia (TIM). It provides an in-depth ... well as regional market drivers and restraints. The study ... and market attractiveness, both for digital and computed radiography. ...
(Date:2/2/2016)... Feb. 2, 2016  Based on its recent ... Sullivan recognizes US-based Intelligent Retinal Imaging Systems (IRIS) ... Award for New Product Innovation. IRIS, a prominent ... North America , is poised to set ... diabetic retinopathy market. The IRIS technology presents superior ...
Breaking Biology News(10 mins):